Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
John P. Gibbs(Takeda (United States)), Maurice G. Emery(Amgen (United States)), J. Greg Slatter(Amgen (United States)), Clapton Dias(Janssen (United States)), Scott M. Wasserman(Amgen (United States)), Michelle Geller, Jessica Johnson(University of North Carolina at Chapel Hill), Ogo Egbuna(Amgen (United States)), Ren Xu(University of British Columbia), Lisa Hamilton(Amgen (United Kingdom))
Cited by 25
Related Papers
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
De novo mutations in schizophrenia implicate synaptic networks
|Nature|2014|1.7k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Gene expression elucidates functional impact of polygenic risk for schizophrenia
|Nature Neuroscience|2016|1.2k